The oral thrombin inhibitor dabigatran: Strengths and weaknesses

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 7-15

  Schulman, Sam ^a,b   Majeed, Ammar ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Malar Hospital   (Sweden)

Author keywords

bleeding; dabigatran; efficacy; low molecular weight heparin; warfarin

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOTRANSFERASE; AMIODARONE; ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; APIXABAN; BILIRUBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; CARBAMAZEPINE; DABIGATRAN ETEXILATE; ENOXAPARIN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; QUINIDINE; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOVERSION; CLINICAL STUDY; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOMA; HEMODIALYSIS; HIP ARTHROPLASTY; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; KIDNEY DYSFUNCTION; KNEE ARTHROPLASTY; LACTATION; LIVER TOXICITY; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOEMBOLISM; UNITED STATES; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84857015242     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300946     Document Type: Conference Paper

References (59)

1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation: 2010; 121 13 1523 1532
2. Hirsh J, ODonnell M, Weitz JI. New anticoagulants. Blood: 2005; 105 2 453 463 (Pubitemid 40070721)
3. Melagatran/ximelagatran: market withdrawal. Prescrire Int: 2006; 15 83 108
4. Testa L, Andreotti F, Biondi Zoccai GG, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. Int J Cardiol: 2007; 122 2 117 124 (Pubitemid 47559087)
5. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol: 2007; 64 3 292 303 (Pubitemid 47283865)
6. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet: 2008; 47 1 47 59 (Pubitemid 350260888)
7. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos: 2008; 36 2 386 399 (Pubitemid 351185753)
8. Bovio JA, Smith SM, Gums JG. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease. Ann Pharmacother: 2011; 45 5 603 614
9. European Public Assessment Report (EPAR). PRADAXA EPAR, summary for the public. 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Summary-for-the-public/human/000829/WC500041060.pdf. Accessed May, 2011
10. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Summary-for-the-public/human/000829/WC500041060.pdf. Accessed May 2011
11. European Medicines Agency. Pradaxa. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific- information-after-authorisation/human/000829/WC500041063.pdf. Accessed December 2011
12. Schulman S, Kearon C, Kakkar AK., et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
13. Connolly SJ, Ezekowitz MD, Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
14. Eriksson BI, Dahl OE, Huo MH., et al. RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost: 2011; 105 4 721 729
15. Eriksson BI, Dahl OE, Rosencher N., et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost: 2007; 5 11 2178 2185 (Pubitemid 47617868)
16. Eriksson BI, Dahl OE, Rosencher N., et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet: 2007; 370 9591 949 956 (Pubitemid 47393577)
17. Ginsberg JS, Davidson BL, Comp PC., et al. RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty: 2009; 24 1 1 9
18. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol: 2010; 30 10 1885 1889
19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 160S 198S (Pubitemid 351892967)
20. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ.; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 454S 545S (Pubitemid 351892971)
21. Nagarakanti R, Ezekowitz MD, Parcham-Azad K., et al. Abstract 4629: Long-term open label extension of the prevention of embolic and thrombotic events on dabigatran in atrial fibrillation (PETRO- Ex study). Circulation: 2008; 118 S-922
22. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost: 2009; 15 Suppl 1 9S 16S
23. van Ryn J, Stangier J, Haertter S., et al. Dabigatran etexilatea novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 6 1116 1127
24. Schulman S, Kakkar AK, Schellong S., et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Proceedings of American Society of Hematology Conference, San Diego 2011:Abstract 205
25. Schulman S, Baanstra D, Eriksson H., et al. the RE-SONATE Study Group. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost: 2011; 9 Suppl 2 22 (Abstr. O-Mo-037)
26. Schulman S, Eriksson H, Goldhaber S., et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost: 2011; 9 Suppl 2 731 732 (Abstr. O-Thu-033)
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA: 2001; 285 22 2864 2870 (Pubitemid 32537350)
28. Singer DE, Albers GW, Dalen JE., et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 546S 592S (Pubitemid 351892972)
29. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med: 2010; 123 7 638 645.e4
30. Nagarakanti R, Ezekowitz MD, Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation: 2011; 123 2 131 136
31. Fiessinger JN, Huisman MV, Davidson BL., et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA: 2005; 293 6 681 689 (Pubitemid 40216038)
32. Bauersachs R, Berkowitz SD, Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
33. Bristol-Myers S. Pfizer. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US).: 2000; [cited 2011 Jun 16]. Available at: http://clinicaltrials.gov/ct2/show/NCT00643201. NLM Identifier: NCT00643201
34. Lee AY, Levine MN, Baker RI., et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med: 2003; 349 2 146 153 (Pubitemid 36818784)
35. Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke: 2010; 41 12 2860 2866
36. Friedman RJ, Dahl OE, Rosencher N., et al. RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res: 2010; 126 3 175 182
37. Sergent O, Ekroos K, Lefeuvre-Orfila L., et al. Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro: 2009; 23 7 1305 1310
38. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos: 2008; 36 2 386 399 (Pubitemid 351185753)
39. Cardiovascular and Renal Drugs Advisory Committee. September 10, 2004. Briefing Information: Exanta. 2004. Available at: http://www.fda.gov/ohrms/ dockets/ac/04/briefing/2004-4069b1.htm. Accessed June, 2011
40. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med: 2010; 363 19 1875 1876
41. Dahl OE, Kurth AA, Rosencher N, Noack H, Clemens A, Eriksson BI. Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement. Int Orthop: 2011;; [Epub ahead of print]
42. Pradaxa: Summary of Product Characteristics. 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf. Accessed May, 2011
43. Safety and Tolerability of Dabigatran Etexilate in Adolescents. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000 [cited 2011 Jun 16]. Available at: http://clinicaltrials.gov/ct2/show/ NCT00844415NLMIdentifier:NCT00844415
44. Boehringer-Ingelheim P. Safety and tolerability of dabigatran etexilate solution in children 1 to <12 years of age. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US).: 2000; [cited 2011 Jun 16]. Available at: http://clinicaltrials.gov/ct2/show/NCT01083732 NLM Identifier: NCT01083732
45. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost: 2003; 89 2 278 283 (Pubitemid 36227279)
46. Flibotte JJ, Hagan N, ODonnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology: 2004; 63 6 1059 1064 (Pubitemid 39287915)
47. van-Ryn J, Rueh D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. In: 13th Congress of the European Hematology Association, June 12-15, 2008. Copenhagen, Denmark: Haematologica; 2008;:148
48. Wolzt M, Levi M, Sarich TC., et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost: 2004; 91 6 1090 1096 (Pubitemid 38821264)
49. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med: 2010; 363 19 1791 1800
50. Aledort LM. Off-label use of recombinant activated factor VIIsafe or not safe? N Engl J Med: 2010; 363 19 1853 1854
51. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet: 2010; 49 4 259 268
52. van Ryn J. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran. Proceedings of the American College of Cardiologists Annual Conference, New Orleans, April 2011. e-abstract 1142-367
53. Apostolakis S, Shantsila E, Lip GY. New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness? Pharmacoeconomics: 2009; 27 10 793 795
54. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics: 2009; 27 10 829 846
55. Wolowacz SE, Roskell NS, Maciver F., et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther: 2009; 31 1 194 212
56. Freeman JV, Zhu RP, Owens DK., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med: 2011; 154 1 1 11
57. Schulman S, Anderson DR, Bungard TJ., et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost: 2010; 8 10 2192 2200
58. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 Suppl 257S 298S (Pubitemid 351892969)
59. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med: 2012;; [Epub ahead of print]